Upstream Bio, Inc (NASDAQ:UPB) IPO will take place October, 11 on the NASDAQ exchange under the ticker UPB.
The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on April 09, 2025.
See also: Benzinga IPO Calendar
About Upstream Bio, Inc
Upstream Bio, Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders and developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ("TSLP"), a cytokine which is a clinically validated driver of inflammatory response positioned
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
